Full list here: T1D The Registry
Vertex VX-880 Islet Cell Infusion Study
Jun 27, 2024Feb 27, 2025
Study Details
New locations have been added for Vertex Pharmaceuticals’ VX-880 clinical trial!
This clinical trial is to evaluating the safety, tolerability and effectiveness of an investigational islet cell infusion called VX-880. The goal of this infusion is to replace the cells that have been lost or don’t work properly in people with type 1 diabetes (T1D).
Eligible participants for this study must meet the following criteria:
- Between the ages of 18 and 65 (inclusive)
- Diagnosed with T1D with history of severe low blood sugars events (hypoglycemia) and reduced ability to recognize low blood sugars (impaired hypoglycemic awareness)
- Blood type A or AB
There are many locations in the United States conducting this study:
California: Los Angeles, San Francisco
Florida: Miami
Illinois: Chicago
Maryland: Baltimore
Massachusetts: Boston
Pennsylvania: Philadelphia, Pittsburgh
Texas: Waco
Virginia: Richmond
Wisconsin: Madison
Participants may be compensated financially for study-related time and reimbursed for travel.
Beyond HbA1c: Expanding Blood Glucose Data Capture with CGM Tracings among Individuals in the T1D Exchange Online Patient Registry
5-10 minutes
Study Details
T1D Exchange is seeking participants for an online study about real-time blood glucose data obtained from continuous glucose monitors (CGMs) and diabetes management in individuals living with type 1 diabetes (T1D). We are recruiting participants who currently use a CGM as part of a T1D therapy regimen, and who are willing to share their CGM data with the T1D Exchange Registry.
The CGM-sharing process is expected to take about 5-10 minutes to complete. You’ll be compensated with a $25 electronic Tango gift card upon completion of the sharing process. Please note that gift cards may take up to 30 days to be emailed after you complete your participation in the study.
Who is eligible?
You may be eligible to participate in this study if you:
- At least 18 years of age and have been diagnosed with type 1 diabetes (T1D)
- Has used or currently uses a continuous glucose monitor (CGM) as part of a T1D therapy regimen for a minimum of 6 months prior to consent
- Have used Dexcom Clarity’s platform with your CGM for a minimum of 6 months prior to consent
- Willing to share historic CGM data (minimum of 6 months of historic data) and future CGM data (minimum of 2 weeks of future data) with T1D Exchange
We hope to expand to other device companies and age groups in the future.
To see if you qualify, please click the link to be taken to the study consent form. By clicking on the link, you’ll be leaving the T1D Exchange Registry and directed to a separate website for this study.
If you have questions about this study, please contact Research@T1DExchange.org.
Thank you for your interest!
Zucara Pharmaceuticals’ Nighttime Hypoglycemia Study
Oct 31, 2024Dec 30, 2024
Study Details
Purpose of the Study
The purpose of this clinical trial is to see if an investigational medication, ZT-01, may help prevent nighttime hypoglycemia (low blood sugar) in adults with type 1 diabetes.
If it is determined you may qualify and if you provide permission, your contact information will be shared with clinical trial study staff. You will then be contacted by your local study site with follow-up information about this trial.
About the Investigational Drug
The study drug is called ZT-01 and is an investigational medication for adults living with T1D who have recently experienced nighttime hypoglycemia.
Participants in this clinical trial will take an injection on a daily basis for a 28-day period. They will then stop taking injections for at least 14 days before starting to take daily injections again for a second 28-day period.
The study requires six in-person visits and two phone calls over this time period.
The clinical trial research staff will communicate other requirements.
What to Expect
To get started, please take the eligibility survey. If you meet the inclusion criteria for the clinical trial and agree to have your contact information shared with the study staff, you will be contacted by the study site nearest to you. Then, your local study site coordinator will share additional information about this study and how to enroll.
If you are eligible and choose to enroll in the clinical trial, you can expect to answer some follow-up eligibility questions. Participation in the clinical trial lasts approximately 16 weeks and requires you to attend six visits at the study center closest to you. Participants will also have phone calls with their study staff on several occasions.
Eligibility:
Eligible participants must meet the following criteria:
- Aged 18 to 75
- Lived with type 1 diabetes for at least 5 years
- Have experienced low glucose levels during the night
By clicking on the link, you’ll be leaving the T1D Exchange Registry.
T1D Exchange is not a sponsor and is not administering this clinical trial, nor are we implying that you will qualify. We are sharing this research opportunity with you so you can decide whether to seek more information or participate.